Given that DLBCL is the most common aggressive lymphoid cancer [22] and that patients who are not cured with R-CHOP have dismal prognosis, novel strategies to overcome R-CHOP resistance are urgently needed. The gene discussed is DDIT3; the disease is lymphoma.